Form 4: BioXcel Therapeutics CLO Javier Rodriguez RSU Vesting

Chief Legal Officer Javier Rodriguez acquired 9,000 shares of BioXcel Therapeutics common stock following the vesting of restricted stock units.

Summary

• Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary, acquired 9,000 shares of common stock.
• The acquisition resulted from the vesting of 9,000 Restricted Stock Units (RSUs) granted on August 1, 2025.
• Following this transaction, the reporting person holds a total of 15,863 shares of common stock.
• The transaction occurred on May 1, 2026, with the RSUs converting to common stock at a price of $0 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard administrative equity compensation transaction rather than a market-moving strategic move.

Positives

• The transaction reflects the fulfillment of equity-based compensation incentives for a key executive.
• The executive maintains a direct ownership stake in the company, aligning interests with shareholders.

Negatives

• None identified; this is a routine equity compensation event.

Risks

• The vesting of equity is subject to continued employment with the issuer or its subsidiaries.

Future Outlook

No forward-looking guidance regarding company performance was provided in this filing.

Management Comments

• The transaction was executed pursuant to the terms of the RSU grant agreement dated August 1, 2025.

Industry Context

StockSavvy.ai notes that routine equity vesting for C-suite executives in the biotechnology sector is standard practice for retention and compensation, and this filing does not signal a change in strategic direction or market sentiment.

Comparison to Industry Standards

• The use of RSU vesting as a component of executive compensation is consistent with standard practices at peer biotech firms such as Axsome Therapeutics or Intra-Cellular Therapies.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine compensation event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation